Market Newsdesk

SPRINGDALE, Ark., Aug. 24, 2026 (GLOBE NEWSWIRE) — Today, Tyson Foods announced a $1 million commitment over the next two years in support of the Harvest to Hallways initiative, advancing efforts to improve childhood nutrition and food access.

Funding from the commitment will help expand student access to healthy school meals, support nutrition education and strengthen meal access in rural communities.

Tyson Foods will leverage its existing partnerships with GENYOUth, Boys & Girls Clubs of America and the Food Research & Action Center (FRAC) to help deliver these programs in schools and communities across the country.

“At Tyson Foods, our purpose is to feed the world like family, and that starts with helping children access the nutrition they need to reach their full potential,” said Donnie King, President & CEO of Tyson Foods. “We’re proud to support the Harvest to Hallways initiative and work alongside organizations that are making a meaningful difference for students and families across the country.”

The Harvest to Hallways initiative brings together public and private sector partners to support healthier school meals, nutrition education and improved food access for children nationwide.

Tyson Foods’ $1 million commitment will be distributed over two years through its nonprofit partners, with programs focused on:

• Expanding access to healthy school meals through innovative school nutrition solutions
• Supporting nutrition education and resources for schools
• Increasing meal access for children in rural communities

For more information about Tyson Foods’ community impact and food access initiatives, visit TysonFoods.com.

About Tyson Foods, Inc.

Tyson Foods, Inc. (NYSE: TSN) is a world-class food company and recognized leader in protein. Founded in 1935 by John W. Tyson, it has grown under four generations of family leadership. The Company is unified by this purpose: Tyson Foods. We Feed the World Like Family™ and has a broad portfolio of iconic products and brands including Tyson®, Jimmy Dean®, Hillshire Farm®, Ball Park®, Wright®, State Fair®, Aidells® and ibp®. Tyson Foods is dedicated to bringing high-quality food to every table in the world, safely and affordably, now and for future generations. Headquartered in Springdale, Arkansas, the Company is a member of the S&P 500 and Russell 1000 large capitalization indices. It had approximately 133,000 team members on September 27, 2025. Visit www.tysonfoods.com.

[email protected]

Orlando, FL, Aug. 24, 2026 (GLOBE NEWSWIRE) —
Coda Octopus Group, Inc. (“CODA” or the “Company”) (NASDAQ: CODA), a global market leader in real-time 3D/4D/5D and 6D imaging sonar technology for real-time subsea intelligence and new generation augmented reality diving technology (“DAVD”), will host a conference call on Monday, September 14, 2026 at 10:00 a.m. Eastern time to discuss its financial results for the fiscal third quarter ended July 31, 2026. A press release detailing these results will be issued before the opening of trading on September 14, 2026.

The Company’s management will provide prepared remarks, followed by a question-and-answer period.

Date: Monday, September 14, 2026
Time: 10:00 a.m. Eastern time (7:00 a.m. Pacific time)
U.S. dial-in numbers: 1-877-451-6152 or 1-201-389-0879
International number: 1-201-389-0879
Conference ID: 13762021

The conference call will broadcast live and be available for replay here.

Persons interested in attending are required to call the conference telephone number approximately 10 minutes before the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please press *0.

A replay of the call will be available after approximately 2:00 p.m. Eastern time on the same day through Monday, September 28, 2026 at 11:59 p.m. ET.

Telephone replay numbers: 1-844-512-2921 or 1-412-317-6671
International replay number: 1-412-317-6671
Access ID: 13762021

About Coda Octopus Group, Inc.

The Company, founded in 1994, is an established supplier to the underwater and subsea market. The Company supplies a range of proprietary hardware and software solutions, including its market-leading real-time 4D/5D/6D imaging sonar technologies, marketed under the names Echoscope^®, Echoscope PIPE^® and Echoscope PIPE NANO Gen Series^®, as well as its next-generation diving technology, the Diver Augmented Vision Display (“DAVD”) system.

The Company’s Echoscope PIPE^® sonar technology generates real-time 3D/4D/5D imagery of moving objects underwater, including in zero-visibility conditions. Echoscope technology is used globally across numerous commercial offshore and defense subsea applications.

Applications for Echoscope^® technology include subsea mapping, intervention and asset placement; salvage and recovery; search and rescue; offshore renewable energy projects, including cable installation and surveys; marine construction; subsea infrastructure installation; mining; robotics and 3D perception; breakwater construction and monitoring; decommissioning; diving operations; and port and harbor security.

The Company’s recently launched DAVD technology is designed to enhance commercial and defense diving operations by providing a fully integrated system that connects topside personnel and divers. The system enables both parties to visualize the same underwater scene and exchange critical information in real time. DAVD also integrates the Company’s sonar technology, enabling dive operations to be conducted in zero-visibility conditions, a common challenge in underwater environments.

The Company also includes two discrete Defense Engineering Services businesses, Coda Octopus Martech Ltd (UK-based) and Coda Octopus Engineering, Inc. (US-based), which principally supply mission-critical sub-assemblies as subcontractors to major defense prime contractors. Their scope of supply typically includes concept development, design, prototyping, manufacturing and post-sale support. This business model provides the potential for repeat orders throughout the life cycle of the underlying defense programs.

The Company recently acquired Precision Acoustics Limited (“PAL”), an acoustic sensors and materials business. PAL supplies acoustic sensors and materials and performs calibration services for medical devices. PAL is accredited to the ISO/IEC 17025 standard and is one of a limited number of organizations in the United Kingdom accredited to perform these specialized measurements. Globally, only a small number of facilities hold ISO/IEC 17025 accreditation for these measurements.

Ultrasonic free-field sensitivity calibration is critical for markets that require precision ultrasonic measurement, strict safety compliance and full metrological traceability. These include regulated and high-risk applications such as diagnostic and therapeutic medical ultrasound, defense and underwater acoustics, where free-field calibration is essential to ensure accurate beam sensitivity and minimize interference. PAL’s operations are based in the United Kingdom.

For further information, please visit Coda Octopus Group or contact us at [email protected].

Forward Looking Statements

This press release contains forward-looking statements concerning Coda Octopus Group, Inc. within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this document, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect”, “assume” and similar expressions are intended to identify forward‐looking statements. Those forward-looking statements include, without limitation, statements regarding the Company’s expectations for the growth of the Company’s operations and revenue. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not limited to, fluctuations in foreign exchange rates, changes in global economic conditions, tariff and trade policies, reductions in defense spending, changes in customer demand, geopolitical developments, the outcome of our ongoing research and development efforts relating to our products, including our patented real-time 3D solutions and DAVD technology, our ability to expand our sales and marketing capabilities, and the other risk factors described in our Annual Report on Form 10-K for the year ended October 31, 2025, filed with the Securities and Exchange Commission on January 29, 2026, as amended by Form 10-K/A filed on February 26, 2026.

Coda Octopus Group, Inc., does not undertake and specifically disclaims any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact:

Mr. Dillon King
Investor Relations
Coda Octopus Group, Inc.
Email: [email protected]
Tel: +1-407-735-2406

SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a Virtual Commercial Day on Wednesday, September 2, 2026, from 8:00 – 9:30 a.m. ET.

Belite Bio’s management team will be joined by leading experts in ophthalmology and people living with Stargardt disease type 1 (STGD1), and will provide an overview of STGD1, the unmet need of people living with the disease, and the current treatment landscape. Management will also provide an update on the Company’s prelaunch preparedness strategies and the potential commercial opportunity for tinlarebant in STGD1, if approved by the U.S. Food and Drug Administration (FDA).

In August 2026, the FDA accepted and granted Priority Review designation of the New Drug Application for tinlarebant for the treatment of STGD1. The FDA has set a Prescription Drug User Fee Act date of February 12, 2027.

Webcast Information

Date: Wednesday, September 2, 2026
Time: 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time)
Webcast Link: https://events.q4inc.com/attendee/785241581

Webcast Link Instructions

A webcast of the event can be accessed and a replay will be archived under “Events” in the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events.

About Belite Bio

Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult subjects with STGD1, which met its primary endpoint, and the drug is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent and adult subjects with STGD1 and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at www.belitebio.com.

Media and Investor Relations Contact:

[email protected]

New York, NY, Aug. 24, 2026 (GLOBE NEWSWIRE) —  Alpha Compute Corp. (NASDAQ: ALP) (“Alpha Compute” or the “Company”), a high-performance GPU infrastructure and confidential-compute technology company serving the artificial intelligence economy, today announced additional appointments to its Global Infrastructure Business.

The appointments are designed to enhance the technical execution and client support team behind a rapidly growing Global Infrastructure sales pipeline.

Anne Schoofs has been appointed Vice President, Client Success, Global Infrastructure Business, where she will lead the charge in managing our strategic enterprise accounts, ensuring that our clients’ high-density compute and AI infrastructure deployments operate at peak efficiency. Her leadership will be instrumental in driving seamless technical onboarding, optimizing workload performance, and building enduring partnerships as we expand our global data center capabilities.

Jose Rios joins as Advisor, Global Infrastructure Business, providing counsel on silicon strategy, high-density compute architecture, and data center design as the Company scales its Blackwell-class fleet.

“As demand for high-density, AI-ready compute accelerates, our ability to deliver is about the people who make sure every deployment performs flawlessly from day one,” said Brittany Kaiser, CEO of Alpha Compute. “Anne’s track record turning enterprise relationships into long-term partnerships, paired with Jose’s deep silicon and data center expertise, gives us exactly the execution muscle we need to scale responsibly against a $1.5 billion pipeline. We’re building the infrastructure backbone of the AI economy, and that requires the best operational talent in the industry, which is exactly what these appointments bring to Alpha Compute.”

About the Appointees

Anne Schoofs — Vice President, Client Success, Global Infrastructure Business

Schoofs brings over two decades of Fortune 500 client account management with deep expertise in enterprise relationship management and technical onboarding at Sprint, Wipro, ATOS/Maven, and SymphonyAI.  She holds a bachelor of arts with honors from Harvard University where she was a member of their varsity women’s golf team.  She also studied data science at Johns Hopkins University. LinkedIn:linkedin.com/in/anneschoofs

Jose Rios — Advisor, Global Infrastructure Business

Rios is the former Vice President and General Manager of Custom Solutions (Data Center and AI) at Intel, with roughly 25 years in compute infrastructure and silicon. At Intel, he led data center programs and custom silicon efforts spanning gaming, and autonomous driving. LinkedIn:linkedin.com/in/siliconjose

About Alpha Compute Corp. 
Alpha Compute Corp. (Nasdaq: ALP) is a vertically integrated AI infrastructure company specializing in GPU-as-a-service and AI Confidential Compute. Alpha Compute’s mission is to support clients, subsidiaries, and partners across critical sectors including: finance, defense, intelligence, and media with the essential framework for any organization requiring secure, confidential computing environments. For more information, please visit: https://www.alphacompute.ai/ 

Alpha Compute Corp is domiciled in the British Virgin Islands with offices in New York, Los Angeles, Miami, Amsterdam and Toronto. Alpha Compute is a founding partner of the Right2Compute Coalition; more information is available at www.right2compute.com 

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements other than statements of historical fact, including those preceded by, followed by, or incorporating words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plans,” “may,” “will,” “potential,” “continues,” or similar expressions are forward-looking statements. 

These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including: the timing and progress of the Company’s strategic initiatives; reliance on third-party vendors and partners; the ability to secure additional financing; uncertainty around the Company’s investments and legacy business; risks related to technology platforms and ecosystems; and general market and economic conditions. A more complete discussion of these risks is set forth under “Item 3 – Key Information – Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended March 31, 2026. 

Undue reliance should not be placed on these forward-looking statements. The forward-looking statements contained herein are made as of the date of this press release, and the Company undertakes no obligation to update or revise them publicly, except as required by law. 

Investor & Media Contact 
Alpha Compute Corp. 
[email protected] 
www.alphacompute.ai 

ir(at)alphacompute.ai 

CHICAGO, Aug. 24, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it is projecting Oliv18™ to generate over $6 million in incremental annual U.S. revenue within the next 12 to 18 months, representing approximately $4.3 million in gross profit at an expected gross margin of approximately 72%.

Oliv18™ is part of the Company’s “18 Series,” a growing portfolio of science-based nutraceutical products. It is a whole olive polyphenol formulation, USDA and EU organic certified and produced through a 100% solvent-free process, entering the U.S. market across the cardiovascular health and antioxidant categories.

The Company’s projection is underpinned by a staged rollout beginning with direct-to-consumer e-commerce, with planned expansion into selected retail channels over time. The forecast incorporates internal assumptions around pricing, anticipated sales volumes, repeat purchase behavior, and distribution growth, and remains subject to the continued execution of the Company’s commercialization plans.

According to Grand View Research, the U.S. cardiovascular health supplements market was estimated at $2.11 billion in 2024 and is projected to reach $3.27 billion by 2030. The U.S. antioxidants market was valued at $1.66 billion in 2025 and is projected to nearly double to $3.18 billion by 2035, according to Precedence Research.

Greg Siokas, CEO of Cosmos Health, stated: “Oliv18™ extends our 18 Series into two established categories in consumer wellness, where demand continues to shift toward products supported by scientific substantiation. We believe it has the potential to become a meaningful revenue contributor to our nutraceutical portfolio as we scale distribution.”

About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.

Investor Relations Contact:

BDG Communications
[email protected]

BIRMINGHAM, Ala., Aug. 24, 2026 (GLOBE NEWSWIRE) — ServisFirst Bank, a subsidiary of ServisFirst Bancshares (NYSE:SFBS), is pleased to announce they have ranked sixth in the top-performing United States banks with between $10 billion to $50 billion in assets, according to American Banker’s annual list. The banks are ranked by the consulting firm Capital Performance Group based on their three-year average return on average equity, or ROAE, using data from year-end 2025. Previously, ServisFirst Bancshares, Inc. was ranked fifth based on year-end 2024 data.

“Being recognized among the country’s top-performing banks is a meaningful reflection of the consistency and commitment of our entire team,” states Tom Broughton, ServisFirst Bank Chairman, President, and CEO. “Our performance is rooted in staying focused on our customers, making thoughtful decisions and maintaining the high standards we have set for ourselves since the Bank was founded. We are proud of what our team has accomplished and grateful for the trust our customers and shareholders continue to place in us. We remain focused on carrying that momentum forward as we grow and serve our markets.”

ServisFirst Bancshares, Inc., an $18 billion-asset institution, reported a three-year average ROAE of 15.39% and reported a 2025 net interest margin of 3.12%.

In the American Bankerarticle, Claude Hanley, founder and partner at Capital Performance Group, said one of the biggest differences between the top-performing banks and the broader group was funding. The top 10 held a larger share of low-cost demand deposits, such as checking and money market accounts, giving them a cheaper source of funding for loans and helping preserve margins even as interest rates declined. Hanley also said there was no huge turnover among the top 10 performers, adding that the banks included in the ranking “outperformed in almost every aspect.”

As the only Alabama-based institution to rank in the top ten, ServisFirst Bank continues to strengthen its reputation as a high-performing, well-capitalized financial institution. This recognition underscores the Bank’s ability to deliver strong financial results in a competitive market, reinforcing its role as a trusted partner for businesses and individuals across the Southeast.

For more information regarding ServisFirst Bank’s recent American Banker ranking, please contact Krista Conlin at [email protected]. For more about ServisFirst Bank, please visit www.servisfirstbank.com.

ABOUT SERVISFIRST BANK

ServisFirst Bank is a full-service commercial bank focused on commercial banking, correspondent banking, treasury management, private banking and the professional consumer market, emphasizing competitive products, state-of-the-art technology and a focus on quality service. Recently, the Bank announced that its assets exceed $18 billion. The Bank offers sophisticated treasury management products, Internet banking, home mortgage lending, remote deposit express banking, and highly competitive rates. 

ServisFirst Bank was formed in May 2005, and has offices in Alabama, Florida, Georgia, North Carolina, South Carolina, Tennessee, Texas, and Virginia. In April 2015, and annually thereafter, ServisFirst Bank has earned investment- grade ratings and a stable outlook from Kroll Bond Rating Agency (KBRA), which measures companies’ financial fundamentals. ServisFirst Bancshares, Inc. files periodic reports with the U.S. Securities and Exchange Commission (SEC). Copies of its filings may be obtained at www.servisfirstbancshares.com.

FOR INFORMATION CONTACT

Krista Conlin, [email protected]

NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP, a nationally recognized securities litigation law firm, reminds investors that a securities fraud class action lawsuit has been filed against Microvast Holdings, Inc. (NASDAQ : MVST) (“Microvast” or the “Company”), on behalf of those who purchased or acquired Microvast common stock between April 1, 2025 and March 16, 2026, inclusive.

PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION

Investors who purchased Microvast shares during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for September 21, 2026.

The filed complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:

• due to, inter alia, inventory management issues and delays in commercial vehicle rollouts by Microvast’s customers, Defendants had overstated Microvast’s ability to reach its margin targets;
• Defendants overstated Microvast’s ability to complete the Huzhou Phase 3.2 expansion by the end of 2025; and
• as a result, Defendants’ public statements were materially false and misleading at all relevant times.

The market received its first hint of the true state of Microvast’s business and operations on June 25, 2025, when the short seller, Grizzly Research, issued a report concerning Microvast (the “Grizzly Report”), alleging that the Company “is fabricating a significant part of its business and capabilities”, including, inter alia, by overstating the level of activity at its production facilities, including the Huzhou facility, and likewise overstating the prospective economic opportunities from its commercial partnerships.

Following publication of the Grizzly Report, Microvast’s stock price plunged during intraday trading, falling as much as $0.40 per share, or approximately 10.23%, before ultimately closing at $3.90 per share. Then, barely one month after the Grizzly Report, on August 1, 2025, Microvast announced the departure of its Chief Financial Officer, Charles Schultz, just three months after he joined the Company. On this news, Microvast’s stock price fell $0.30 per share, or approximately 9.93%, to close at $2.72 per share on August 4, 2025.

Subsequently, operating results for the quarter ended September 30, 2025, in which it revealed that production following the Huzhou Phase 3.2 expansion would not begin until Q1 2026 – after repeatedly advising investors that the additional capacity associated with the expansion would be online by Q4 2025. On this news, Microvast’s stock price fell $0.50 per share, or approximately 10%, to close at $4.48 per share on November 11, 2025.

Finally, on March 16, 2026, Microvast issued a press release reporting its financial and operating results for the quarter and year ended December 31, 2025. Among other items, Microvast reported that gross margin declined to approximately 1% for the quarter, down sharply from approximately 36% for the same period in the prior year, which the Company attributed to inventory impairment charges arising from “specialized ESS components”. Microvast also reported revenue of $96.5 million for the quarter, representing a 15% year-over-year decrease and falling well short of the consensus estimate of $136.4 million. Microvast attributed this result to “regulatory shifts in South Korea and delays in customer platform ramp-up” in Europe, the Middle East, and Africa.

On this news, Microvast’s stock price fell $0.79 per share, or 34.2%, to close at $1.52 per share on March 17, 2026.

WHY WOLF HALDENSTEIN?

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

There is no cost or obligation to speak with an attorney.

Contact:

• Phone: (800) 575-0735 or (212) 545-4774
• Email: 
  [email protected]
• Contact Person: Gregory Stone, Director of Case and Financial Analysis

Firm Website:
 Wolf Haldenstein Adler Freeman & Herz LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Lead Plaintiff Deadline September 14, 2026

NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP, a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against GPGI, Inc. (“GPGI”) (NYSE: GPGI), on behalf of those who purchased or acquired GPGI Class A common stock between November 3, 2025 and May 6, 2026, inclusive.

PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION

Investors who purchased GPGI shares during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for September 14, 2026.

Main Allegations:

The filed complaint alleges that GPGI made materially false statements regarding:

1. Overstating the value of Husky Technologies Limited (“Husky”) (acquired in January 2026)
2. Husky failing to meet projected revenue and EBITDA targets
3. The acquisition being primarily motivated to generate fees for Resolute Holdings (“Resolute”) rather than create shareholder value
4. Defendants’ statements lacking reasonable factual basis

Stock Performance Decline:

• March 12, 2026: After Q4 2025 results showing EBITDA decline, stock dropped 16.4% ($3.23/share)
• May 7, 2026: After Q1 2026 results showing further deterioration and guidance cuts, stock dropped 25.9% ($4.52/share)

Timeline Context:

• August 2024: Resolute acquisition announced
• January 2026: Husky acquisition completed
• February 2026: Negative research report published
• March-May 2026: Stock decline events

WHY WOLF HALDENSTEIN?

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

There is no cost or obligation to speak with an attorney.

Contact:

• Phone: (800) 575-0735 or (212) 545-4774
• Email: 
  [email protected]
• Contact Person: Gregory Stone, Director of Case and Financial Analysis

Firm Website:
 Wolf Haldenstein Adler Freeman & Herz LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Assets in the Fund have doubled since April, with the $200 million milestone arriving less than two weeks after JEDI announced it was the first ETF with indirect exposure to Shield AI, the privately held autonomy company behind the Hivemind AI pilot and the V-BAT aircraft.

MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) — Defiance ETFs today announced that the Defiance Drone & Modern Warfare ETF (NYSE: JEDI) has surpassed $200 million in assets under management as of August 21, 2026, less than eleven months after the Fund’s September 25, 2025 launch. The milestone comes less than two weeks after Defiance announced that JEDI had become the first ETF to provide indirect exposure to Shield AI (SHAI.PVT), the privately held defense autonomy company, through an interest in a single-asset special purpose vehicle.

Accelerating Adoption

JEDI
crossed $100 million in assets on April 20, 2026, less than seven months after launch. Four months later, those assets have doubled. The mandate has grown along with them. A supplement to the Fund’s prospectus dated July 27, 2026 added a secondary investment objective: with respect to up to 15% of the Fund’s net assets, from time to time and at the Adviser’s discretion, the Fund seeks to provide exposure to companies that would have qualified for inclusion in the BITA Drone & Modern Warfare Select Index except that their securities are not publicly traded. On August 11, 2026, Defiance announced that JEDI had put that mandate to work, bringing Shield AI exposure into the portfolio.

JEDI targets the companies rebuilding modern defense around drones, autonomous systems, and AI-driven capabilities across land, sea, air, and space. All of it sits in an ETF structure, with full holdings published daily and shares tradable throughout the trading day.

“Crossing $200 million in under a year tells us the thesis is landing,” said Sylvia Jablonski, Chief Investment Officer of Defiance ETFs. “Modern warfare is undergoing a paradigm shift around drones, autonomy, and software, and investors increasingly want that entire stack in a single ticker. Bringing Shield AI into the fund was about completing that picture, because the companies defining this category are not all public yet. Shareholders should not have to wait for an IPO to hold one of the companies at the forefront of autonomy in defense, and this milestone tells us they agree.”

The Shield AI Exposure

The Fund holds its Shield AI exposure indirectly, through an interest in a single-asset special purpose vehicle sponsored by an unaffiliated third party that holds Shield AI securities. As of August 20, 2026, the position represented approximately 2.44% of the Fund’s net assets.

Founded in 2015 and headquartered in San Diego, Shield AI builds autonomy software and aircraft for defense applications. The company’s Hivemind AI pilot enables aircraft to operate in environments where GPS and communications links are jammed or denied, and the company has described Hivemind as continuously deployed in real-world operational environments since 2018. In June 2026, the U.S. Air Force awarded Shield AI a production contract to implement Hivemind as mission autonomy software for the Collaborative Combat Aircraft program. The company’s MQ-35 V-BAT, a vertical takeoff and landing unmanned aircraft system requiring no runway or launch infrastructure, has been procured by the U.S. Coast Guard and allied militaries including the Netherlands Ministry of Defence. In March 2026, Shield AI announced a $2 billion raise at a $12.7 billion post-money valuation, led by Advent International with participation from the Strategic Investment Group of JPMorganChase’s Security and Resiliency Initiative and funds managed by Blackstone.

About Defiance ETFs

Defiance ETFs is a leading issuer of thematic, income, and leveraged exchange-traded funds with more than $12 billion in assets under management. Founded in 2018, Defiance has established itself as a first mover in select thematic categories including AI infrastructure, quantum computing, and drone and modern warfare technology. For more information, visit www.defianceetfs.com.

* As of August 7, 2026, based on a review of SEC EDGAR filings, publicly available ETF issuer holdings disclosures, and U.S. and non-U.S. exchange listings, Defiance ETFs has identified no other exchange-traded fund that holds or has held securities of Shield AI, Inc., a privately held defense technology company, and accordingly believes the Defiance Drone & Modern Warfare ETF (NYSE: JEDI) is the first ETF to hold Shield AI.

IMPORTANT DISCLOSURES

Shield AI is not affiliated with, and does not sponsor, endorse, or promote, Defiance ETFs or the Fund. References to Shield AI are not a recommendation to buy or sell any security. Fund holdings are subject to change and should not be considered investment advice.

The Fund’s investment objectives, risks, charges, and expenses must be considered carefully before investing. The prospectus and summary prospectus contain this and other important information about the investment company. Please read carefully before investing. A hard copy of the prospectuses can be requested by calling 833.333.9383.

Defiance ETFs LLC is the Fund’s investment adviser. The Fund’s sub-adviser is Penserra Capital Management LLC.

Investing involves risk. Principal loss is possible. As an ETF, the Fund may trade at a premium or discount to NAV. Shares of any ETF are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. A portfolio concentrated in a single industry or country may be subject to a higher degree of risk.

Private Company / Privately Offered Securities Risk: Securities of private companies are not traded on an exchange and are typically issued without registration under the Securities Act of 1933. Such investments are subject to significant risks, including illiquidity risk, valuation risk, limited disclosure and lack of certain regulatory protections available to investors in publicly traded securities, exit strategy risk, and the risk of total loss. Private companies may have limited operating histories, unproven business models, and limited access to capital.

Investment Selection Risk (Private Sleeve): The Fund’s investments in privately issued securities are selected by the Adviser in its discretion and are not selected by reference to the Index. Those selection decisions may underperform the Index, other relevant benchmarks, or alternative investments the Adviser could have selected.

Sponsor Dependence Risk: The Fund depends on the SPV sponsor for administration of the SPV, transmission of information rights, the conduct of the SPV’s relationship with the underlying issuer, and implementation of any liquidity event. The SPV sponsor may have interests that diverge from those of the Fund.

Liquidity Risk: The Fund’s SPV interest is not traded on any public market, is not redeemable on demand at the option of the Fund, and may be transferred only with the consent of the SPV sponsor. The Fund’s ability to monetize the investment generally depends on the occurrence of a qualifying liquidity event at the underlying issuer. There is no assurance that any such liquidity event will occur within any particular time frame, on any particular terms, or at all.

Illiquid Investments Risk: The Fund may invest up to 15% of its net assets in illiquid investments. Illiquid investments may be difficult or impossible to sell at the time or price desired, may be sold at a substantial discount to carrying value, and may adversely affect the Fund’s ability to meet redemption requests.

Valuation Risk: Private company securities are fair valued in accordance with procedures adopted pursuant to Rule 2a-5 under the Investment Company Act of 1940. Fair valuations involve subjective judgments, and the value at which an investment is ultimately realized may differ, potentially materially, from the most recent fair value determination.

Premium/Discount Risk: The Fund’s SPV interest does not have an observable market price during the trading day and is reflected in the Fund’s daily net asset value at fair value. As a result, Fund shares may trade at a premium or discount to net asset value to a greater extent, and with greater volatility, than has historically been the case for the Fund.

Tracking Error / Index Divergence Risk: Because the Fund holds an investment that is not a component of the Index, the Fund’s performance is expected to diverge from the performance of the Index. The magnitude of this divergence may be material.

Concentration Risk: A portfolio concentrated in a single industry or country may be subject to a higher degree of risk than a more diversified portfolio.

Foreign Securities Risk: Investments in foreign securities involve certain risks including risk of loss due to foreign currency fluctuations or to political or economic instability. This risk is magnified in emerging markets.

Small/Mid-Cap Risk: Small and mid-cap companies are subject to greater and more unpredictable price changes than securities of large-cap companies.

Aerospace and Defense Companies Risk: Aerospace and defense companies rely heavily on government demand and contracts, making them sensitive to regulation, budget changes, and spending policies that can significantly affect industry performance.

Drone Companies Risk: Drone companies face risks from changing business cycles, rapid technological change, and government regulation, and may have limited product lines or financial resources. Securities of smaller drone companies tend to be more volatile than those of companies that do not rely heavily on technology.

Non-Diversification Risk: The Fund may invest a larger portion of its assets in fewer issuers than a diversified fund, increasing exposure to the risks of individual companies.

New Fund Risk: The Fund is a recently organized investment company with limited operating history, so prospective investors have a limited track record on which to base their investment decisions.

Effective April 30, 2026, the BITA Drone & Modern Warfare Select Index methodology was updated to expand the list of eligible capability areas, change constituent weighting to a liquidity-momentum factor, and permit between-rebalance additions of high-exposure IPOs and companies pivoting to modern warfare technology. Performance shown for periods prior to April 30, 2026 reflects the Index’s prior methodology and may not be representative of results under the current methodology.

The ‘BITA Drone & Modern Warfare Select Index’ is the exclusive property of BITA GmbH. BITA® is a trademark of BITA GmbH and has been licensed for use for certain purposes by Defiance ETFs LLC. Products based on the BITA Drone & Modern Warfare Select Index are not sponsored, endorsed, sold or promoted by BITA GmbH, and BITA GmbH makes no representation regarding the advisability of trading in such product(s). It is not possible to invest directly in an index.

Diversification does not ensure a profit nor protect against loss in a declining market.

Commissions may be charged on trades.

Distributed by Foreside Fund Services, LLC.

Media Contact:

Brenda Hentschel
[email protected]
201.705.3758

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/3b590799-d080-4b21-88c6-63cf8dee0128

https://www.globenewswire.com/NewsRoom/AttachmentNg/e22ba471-96f7-449e-8fb5-7e81cf860dfd